Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 2, 1996, Pages 218-228

  Canal, Nicola ^a   Imbimbo, Bruno P ^a,b  

^a Medical Department   (Italy)

^b Medical Department   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; HEPTYLSTIGMINE TARTRATE; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; EXTRASYSTOLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERYTHROCYTES; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSOSTIGMINE;

EID: 0029860968     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90138-1     Document Type: Article

References (41)

1. Brufani M, Marta M, Pomponi M. Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia. Eur J Biochem 1986;157:115-20.
2. Brufani M, Castellano C, Marta M, Oliverio A, Pagella PG, Pavone F, et al. A long-lasting cholinesterase inhibitor affecting neural and behavioral processes. Pharmacol Biochem Behav 1987;26:625-9.
3. De Sarno P, Pomponi M, Giacobini E, Tang XC, Williams E. The effect of heptylphysostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat. Neurochem Res 1989;14:971-7.
4. Dawson GR, Bentley G, Draper F, Rycroft W, Iversen SD, Pagella PG. The behavioural effects of heptyl-physostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodents. Pharmacol Biochem Behav 1991;39:865-71.
5. Rupniak NMJ, Tye SJ, Brazell C, Heald A, Iversen SD, Pagella PG. Reversal of cognitive impairment by heptylphisostigmine, a long lasting cholinesterase inhibitor, in primates. J Neurol Sci 1992;107:246-9.
6. Unni LK, Hutt V, Imbimbo BP, Becker RE. Kinetics of cholinesterase inhibition of eptastigmine in man. Eur J Clin Pharmacol 1991;41:83-4.
7. Goldberg MR, Barchowsky A, McCrea J, BenMaimon C, Capra N, Fitzpatrick V, et al. Heptylphysostigmine (L-693,487): safety and cholinesterase inhibition in a placebo-controlled rising-dose healthy volunteer study. Presented at the Second International Springfield Symposium on Alzheimer Therapy, Springfield, Illinois, May 3-5, 1991.
8. Imbimbo BP, Licini M, Schettino M, Mosca A, Zecca L, Radice D, et al. Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers. J Clin Pharmacol 1995;35: 285-90.
9. Swift RH, Mant TG, Heald A, Sciberras DG, Imbimbo B, Morrison PJ, et al. A study to investigate the safety, tolerance, and pharmacodynamics of single rising doses of L-693,487 (heptylphysostigmine tartrate) in healthy elderly volunteers. Presented at the Joint Meeting of the British Pharmacological Society with the Nordic Society, Southampton, England, Sept. 18-20, 1991.
10. Sramek JJ, Block GA, Reines SA, Sawin SF, Barchowsky A, Cutler NR. A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase. Life Sci 1994;56:319-26.
11. Barr RD, Koekebakker M, Lawson AA. Acetylcholinesterase in the human erythron; II: biochemical assay. Am J Hematol 1988;28:260-5.
12. Thomsen T, Kaden B, Fischer JP, Bickel U, Barz H, Gusztony G, et al. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem 1991;29:487-92.
13. Mckhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
14. Folstein MF, Folstein SW, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
15. Loeb C, Gandolfo C. Diagnostic evaluation of degenerative and vascular dementia. Stroke 1983;14:399-401.
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
17. Mosca A, Onelli E, Rosti E, Paleari R, Luzzana M, Imbimbo BP. A non-invasive technique for real-time measurements of acetylcholinesterase activity during monitoring of eptastigmine treatment. Ther Drug Monit 1995;17:230-8.
18. Zecca L, Radice D, Mosca A, Pagella PG. Determination of heptylphysostigmine in plasma by highperformance liquid chromatography with electrochemical detection. J Chromatogr 1993;615:169-73.
19. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychological function. JAMA 1963;85:914-9.
20. Lawton MP, Brody EM. Assessment of older people: self-maintaining and Instrumental Activities of Daily Living. Gerontologist 1969;9:179-86.
21. Spinnler H, Tognoni G, editors. Standardizzazione e Taratura Italiana di Test Neuropsicologici. Ital J Neurol Sci 1987;6(suppl 8):8-120.
22. Leber P. Guidelines for the clinical evaluation of antidementia drugs. Letter to the sponsors involved in clinical trials with drugs in Alzheimer's disease. Rockville, MD: US Food and Drug Administration, Nov. 8, 1990.
23. Bartus RT, Dean RL, Beer B. Memory deficits in aged Cebus monkeys and facilitation with central cholinomimetics. Neurobiol Aging 1980;1:145-52.
24. Ridley RM, Murray TK, Johnson JA, Baker HF. Learning impairment following lesion of the basal nucleus of Meynert in the marmoset: modification by cholinergic drugs. Brain Res 1986;376:108-16.
25. Bartus RT, Johnson HR. Short-term memory in rhesus monkey: disruption for the anticholinergic scopolamine. Pharmacol Biochem Behav 1976;5:39-46.
26. Okazaki Y, Natori K, Irie T, Katsube J. Effects of a novel CNS-selective cholinesterase inhibitor, SM-10888, on habituation and passive avoidance responses in mice. Jpn J Pharmacol 1990;53:211-20.
27. Freedman SB, Harley EA, Bentley G, Dawson GR. Determination of cholinesterase inhibition in erythrocytes, plasma and CSF following administration of eptastigmine and physostigmine at behaviourally active doses in rat [abstract]. Neurobiol Aging 1992; 13(suppl 1):S129.
28. Barenghi L, Ceriotti F, Luzzana M, Ripamonti M, Mosca A, Bonini PA. Measurement of erythrocyte acetylcholinesterase and plasma cholinesterase activity by a differential pH technique. Ann Clin Biochem 1986;23:538-45.
29. Cazzola E, Lattuada N, Zecca L, Radice D, Luzzana M, Imbimbo BP, et al. Rapid potentiometric determination of cholinesterases in plasma and red cells: application to eptastigmine monitoring. Chem Biol Interact 1993;87:265-8.
30. Flood JF, Landry DW, Jarvik ME. Cholinergic receptor interactions and their effects on long-term memory processing. Brain Res 1981;215:177-85.
31. Haroutunian V, Barnes E, Davis KL. Cholinergic modulation of memory in rats. Psychopharmacology 1985;87:266-71.
32. Nabeshima T, Yoshida S, Kameyama T. Effects of the novel compound NIK-247 on impairment of passive avoidance response in mice. Eur J Pharmacol 1988; 154:263-9.
33. Yamazaki N, Kato K, Kurihara E, Nagaoka A. Cholinergic drugs reverse AF64A-induced impairment of passive avoidance learning in rats. Psychopharmacology 1991;103:215-22.
34. Wanibuchi F, Nishida T, Yamashita H, Hidaka K, Koshiya K, Tsukamoto S, et al. Characterization of novel muscarinic receptor agonist, YM796: comparison with cholinesterase inhibitors in in vivo pharmacological studies. Eur J Pharmacol 1994;265:151-8.
35. Peters BH, Levin HS. Memory enhancement after physostigmine treatment in the amnesic syndrome. Arch Neurol 1977;34:215-9.
36. Mohs RC, Davis BM, Johns CA, Mathe AA, Greenwald BS, Horvath TB, et al. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985;142:28-33.
37. Stern Y, Sano M, Mayeux R. Long-term administration of oral phsysotigmine in Alzheimer's disease. Neurology 1988;38:1837-41.
38. Thal LJ, Masur DM, Blau AD, Fuld PA, Klauber MR. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease. J Am Geriatr Soc 1989;37:42-8.
39. Marchi M, Paudice P, Raiteri M. Autoregulation of acetylcholine release in isolated hippocampal nerve endings. Eur J Pharmacol 1981;73:75-9.
40. Consolo S, Ladinsky H, Vinci R, Palazzi E, Wang JX. An in vivo pharmacological study on muscarinic receptor subtypes regulating cholinergic neurotransmission in rat striatum. Biochem Pharmacol 1987;36: 3075-7.
41. Messamore E, Warpman U, Williams E, Giacobini E. Muscarinic receptors mediate attenuation of extracellular acetylcholine levels in rat cerebral cortex after cholinesterase inhibition. Neurosci Lett 1993;158: 205-8.